Article

Ophthalmic solution reformulated as nasal spray for allergies

Fort Worth, TX-A nasal formulation of olopatadine HCl ophthalmic solution 0.1% (Patanol, Alcon) reduced seasonal allergic rhinitis symptoms compared with placebo, according to phase III study results.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Related Content
Children with ADHD may be less likely to develop myopia, study suggests
July 18th 2025

Children with ADHD may be less likely to develop myopia, study suggests

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Study shows ceftriaxone found effective in treating congenital syphilis
June 11th 2025

Study shows ceftriaxone found effective in treating congenital syphilis

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia
June 4th 2025

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia

© 2025 MJH Life Sciences

All rights reserved.